Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.Journal for Immunotherapy of Cancer|June 10, 2022
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapyMichael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, et al.Nature Medicine|September 8, 2025
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analysesJoshua E Reuss, Paul K Lee, Reza J Mehran, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.Journal for Immunotherapy of Cancer|September 15, 2020
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancerJoshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung CancerJiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.Nature Cancer|September 28, 2020
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerValsamo Anagnostou, Noushin Niknafs, Kristen Marrone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.Biorxiv : the Preprint Server for Biology|August 20, 2025
Novel Predictive Spatial Biomarker in Non-Small Cell Lung Carcinoma: The Diversity of Niches Unlocking Treatment Sensitivity (DONUTS)Tricia R Cottrell, Jeffrey S Roskes, Michael Fotheringham, et al.Pageof 6